ORGANIZATION

• Japan Needs Listing Rule Conditional on Possible Ad-Hoc Re-Pricing: Kono
  September 7, 2016

• Kenporen’s Kono Pushes for “Huge Seller” Re-Pricing for Opdivo before 2018
  September 7, 2016

• Hodanren Demands Ad-Hoc Re-Pricing for Opdivo
  September 7, 2016

• Economists, Industry and Regulatory Officials Talk over Pricy Med Issue at JPMA Seminar
  September 6, 2016

• JMA Think Tank Calls for Rewarding Innovation with Subsidies, in Lieu of Pricing
  September 1, 2016

• Drug Wholesalers See 8.3% Boost in Sales on Hep C Demand: JPWA
  August 17, 2016

• JPMA Calls for Financial Support to Encourage R&D on Treatments for ARIs
  August 15, 2016

• Sales Rep Number in Japan Logs Big Drop for 2nd Straight Year: Survey
  August 12, 2016

• EFPIA Japan Calls for Relaxation of Japanese Vaccine Regulations: Vaccine Subcommittee Head
  August 9, 2016

• NPO Petitions Academic Society to Clarify Reason for Deaths Associated with Xeplion
  July 20, 2016

• Japan Biosimilar Association Up and Running with Four Member Firms
  July 19, 2016

• JPMA Keen to Defend R&D Tax Credit System
  July 8, 2016

• Generic Use Rate at 55.7% in FY2015, Up 3.7 Points: JGA
  July 8, 2016

• EFPIA Japan Calls for Diversifying Vaccine Supply Sources to Prepare for Crises
  July 7, 2016

• Drug Damage Watchdog Challenges Doctors’ View, Says HPV Vaccination Shouldn’t Be Recommended
  July 5, 2016

• JMA Vice President Nakagawa Calls for Rules on Use of “Expensive Drugs”
  June 27, 2016

• Yokokura Reelected for Third Term as JMA President
  June 27, 2016

• NPO Asks MHLW to Take Steps to Ensure Proper Use of Xeplion
  June 23, 2016

• PMDA Chief Brings Together Drug Makers, Tech Vendors to Compile Proposal on Digital Health
  June 17, 2016

• Re-Pricing Rules Need Drastic Overhaul, Possible Abolishment Should Be Discussed for Z2: FPMAJ
  June 14, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• …
• Next ›
• 最終 »